Nuozhu Health: 2025 Net Profit of 642 Million Yuan, First Profitable Year Removes Stock Abbreviation Identifier U

MetaMuskRat · 2026-03-25T13:10:17+00:00

Nuoke Health released its annual report with operating revenue of 2.375 billion yuan in 2025 and net profit attributable to shareholders of 642 million yuan. The company's main product Yinuokay® showed significant revenue growth. The company achieved profitability for the first time, and the stock's special identifier U will be removed in 2026.

MetaMuskRat

2026-03-25 13:10:17

Abstract generation in progress

People’s Financial News, March 25 — Nuocheng Jianhua (688428) announced its annual report on March 25. In 2025, the company achieved operating revenue of 2.375 billion yuan, a year-on-year increase of 135.27%. Net profit attributable to shareholders was 642 million yuan, compared to a loss of 441 million yuan in the same period last year. Basic earnings per share were 0.38 yuan. In 2025, the company’s core product, Yinuokai® (Acalabrutinib, a Bruton’s Tyrosine Kinase (BTK) inhibitor), saw strong revenue growth. As of December 31, 2025, the commercialized revenue from Acalabrutinib reached 1.41 billion yuan, a 40.99% increase from 2024. The company’s net profit attributable to shareholders and net profit after deducting non-recurring gains and losses both turned positive in 2025, meeting the criteria of “a non-profitable company achieving its first profit upon listing.” The company’s A-shares will remove the special marker U on March 27, 2026, and the stock abbreviation will change from “Nuocheng Jianhua-U” to “Nuocheng Jianhua.”

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes